Published in Expert Opin Biol Ther on April 12, 2015
CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep (2015) 0.98
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
Transcriptional gene silencing in humans. Nucleic Acids Res (2016) 0.82
HEK293T Cells Are Heterozygous for CCR5 Delta 32 Mutation. PLoS One (2016) 0.75
Applications of CRISPR/Cas9 in retinal degenerative diseases. Int J Ophthalmol (2017) 0.75
HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health (2017) 0.75
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep (2016) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
RNA-programmed genome editing in human cells. Elife (2013) 14.82
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell (2013) 13.43
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013) 11.35
Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol (2005) 11.05
Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (2009) 10.67
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (2014) 10.43
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell (2013) 9.55
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature (2008) 7.64
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol (2014) 6.85
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res (2013) 6.19
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature (2014) 5.70
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell (2014) 5.43
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature (2014) 5.19
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods (2013) 4.85
CRISPR RNA-guided activation of endogenous human genes. Nat Methods (2013) 4.69
Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet (2008) 4.45
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol (2014) 4.41
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med (1997) 4.21
CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res (2013) 4.11
Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature (2014) 3.72
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res (2013) 3.50
The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods (2014) 3.34
The rise of regulatory RNA. Nat Rev Genet (2014) 3.02
HIV-1 proviral DNA excision using an evolved recombinase. Science (2007) 2.81
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med (2014) 2.76
IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2013) 2.68
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell (2014) 2.55
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48
A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol (2010) 2.39
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol (2013) 2.33
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32
A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell (2014) 2.27
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med (1997) 2.15
Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol (2015) 2.03
Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. J Infect Dis (2014) 1.87
Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription (2010) 1.85
Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A (2014) 1.49
Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res (2013) 1.48
Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun (2015) 1.41
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Detection, characterization and regulation of antisense transcripts in HIV-1. Retrovirology (2007) 1.35
Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res (2014) 1.34
CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One (2014) 1.16
An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther (2014) 1.11
Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS (2011) 1.09
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog (2013) 1.08
Human Immunodeficiency Virus-Type 1 LTR DNA contains an intrinsic gene producing antisense RNA and protein products. Retrovirology (2006) 1.07
Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids. Chem Biol (2011) 1.05
HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period. Retrovirology (2012) 0.93
Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase. PLoS One (2012) 0.89
Targeted genome editing tools for disease modeling and gene therapy. Curr Gene Ther (2014) 0.87
Destabilizing domains mediate reversible transgene expression in the brain. PLoS One (2012) 0.85
Intracellular context affects levels of a chemically dependent destabilizing domain. PLoS One (2012) 0.85
In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods (2010) 0.85
Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther (2014) 0.85
Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol (2006) 4.93
Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proc Natl Acad Sci U S A (2007) 3.99
The reality of pervasive transcription. PLoS Biol (2011) 3.41
The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA (2005) 3.14
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol (2013) 2.33
Chromosomal contact permits transcription between coregulated genes. Cell (2013) 1.89
Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription (2010) 1.85
Promoter targeted small RNAs induce long-term transcriptional gene silencing in human cells. Nucleic Acids Res (2009) 1.79
RNA and transcriptional modulation of gene expression. Cell Cycle (2007) 1.56
Profiling microRNA expression with microarrays. Trends Biotechnol (2008) 1.48
Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) (2004) 1.45
Snapshots: chromatin control of viral infection. Virology (2013) 1.39
Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression. Mol Ther (2008) 1.23
Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol (2010) 1.21
Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr Opin Mol Ther (2010) 1.20
An RNA targeted to the HIV-1 LTR promoter modulates indiscriminate off-target gene activation. Nucleic Acids Res (2007) 1.20
The biogenesis and characterization of mammalian microRNAs of mirtron origin. Nucleic Acids Res (2011) 1.20
Interferon-γ and systemic autoimmunity. Discov Med (2013) 1.13
Controlling transcription with noncoding RNAs in mammalian cells. Biotechniques (2010) 1.03
Diurnal expression of functional and clock-related genes throughout the rat HPA axis: system-wide shifts in response to a restricted feeding schedule. Am J Physiol Endocrinol Metab (2009) 1.02
siRNA induced transcriptional gene silencing in mammalian cells. Cell Cycle (2005) 1.02
Long non-coding RNA targeting and transcriptional de-repression. Nucleic Acid Ther (2013) 0.98
The relationship between transcription initiation RNAs and CCCTC-binding factor (CTCF) localization. Epigenetics Chromatin (2011) 0.98
Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One (2009) 0.98
The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One (2008) 0.96
The oncogenic TBX3 is a downstream target and mediator of the TGF-β1 signaling pathway. Mol Biol Cell (2013) 0.96
Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther (2005) 0.95
Balance prostheses for postural control. IEEE Eng Med Biol Mag (2003) 0.95
Are viral-encoded microRNAs mediating latent HIV-1 infection? DNA Cell Biol (2006) 0.93
Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells. Hum Gene Ther (2012) 0.93
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest (2013) 0.92
Differential responses of hypothalamus-pituitary-adrenal axis immediate early genes to corticosterone and circadian drive. Endocrinology (2007) 0.92
Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. Nucleic Acids Res (2012) 0.90
The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5' long terminal repeat. Oligonucleotides (2007) 0.90
Small RNA-Mediated Epigenetic Myostatin Silencing. Mol Ther Nucleic Acids (2012) 0.89
Non-coding RNA and antisense RNA. Nature's trash or treasure? Biochimie (2011) 0.88
An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Mol Ther Nucleic Acids (2013) 0.87
Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicity. Sci Rep (2013) 0.87
Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens Suppl (2006) 0.87
Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease. Sci Rep (2013) 0.87
Long antisense non-coding RNAs and the epigenetic regulation of gene expression. Biomol Concepts (2013) 0.87
Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors. Nucleic Acids Res (2010) 0.86
A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex. J Neurosci (2014) 0.86
Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun (2009) 0.86
Chromatin, non-coding RNAs, and the expression of HIV. Viruses (2013) 0.83
Epigenetic regulation of gene expression in human cells by noncoding RNAs. Prog Mol Biol Transl Sci (2011) 0.82
Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther (2009) 0.82
Pseudogenes: a novel source of trans-acting antisense RNAs. Methods Mol Biol (2014) 0.81
Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. Hum Gene Ther (2013) 0.81
Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol (2004) 0.80
Not so pseudo anymore: pseudogenes as therapeutic targets. Pharmacogenomics (2013) 0.80
Chemically Modified Oligonucleotides Modulate an Epigenetically Varied and Transient Form of Transcription Silencing of HIV-1 in Human Cells. Mol Ther Nucleic Acids (2012) 0.79
Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells. Virol J (2012) 0.79
Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs. Antivir Ther (2012) 0.79
A new world order: tailored gene targeting and regulation using CRISPR. Mol Ther (2014) 0.79
MYCNOS functions as an antisense RNA regulating MYCN. RNA Biol (2015) 0.79
Effective Pol III-expressed long hairpin RNAs targeted to multiple unique sites of HIV-1. Methods Mol Biol (2010) 0.79
Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses (2006) 0.78
Small RNA-induced transcriptional gene regulation in mammals mechanisms, therapeutic applications, and scope within the genome. Prog Mol Biol Transl Sci (2011) 0.78
Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs. Artif DNA PNA XNA (2010) 0.78
Targeted small noncoding RNA-directed gene activation in human cells. Methods Mol Biol (2014) 0.77
Glycated AAV vectors: chemical redirection of viral tissue tropism. Bioconjug Chem (2011) 0.76
HIV Latency and the noncoding RNA therapeutic landscape. Adv Exp Med Biol (2015) 0.76
Transcriptional Gene Silencing of the Autism-Associated Long Noncoding RNA MSNP1AS in Human Neural Progenitor Cells. Dev Neurosci (2016) 0.76
Effects of erythropoietin stimulating agent (ESA) automated adjustment protocols on hemoglobin levels and mortality in end stage renal disease patients. Med Health R I (2012) 0.75
A micromachined surface stress sensor with electronic readout. Rev Sci Instrum (2008) 0.75
Gene therapy and gene transfer approaches to prevent or treat chronic virus infections. Adv Exp Med Biol (2015) 0.75
RNA interference-based gene expression strategies aimed at sustained therapeutic inhibition of HIV. Curr Top Med Chem (2009) 0.75
Construction of mismatched inverted repeat (IR) silencing vectors for maximizing IR stability and effective gene silencing in plants. Methods Mol Biol (2015) 0.75
Acute and chronic renal failure. J Am Podiatr Med Assoc (2004) 0.75
In the first post-genomic decade, the ENCODE and FANTOM consortia have revolutionized. Introduction. Curr Top Microbiol Immunol (2016) 0.75